Quidel Ortho Corp, publicly traded as QDEL, is a leading manufacturer of diagnostic healthcare solutions that empower medical professionals to enhance patient care. Established in 1979 and headquartered in San Diego, California, Quidel Ortho Corp serves to provide reliable, rapid diagnostic testing solutions globally, ideal for a variety of healthcare settings.
These settings include hospitals, laboratories, physician offices, and clinics. The company's core mission is to support improved health outcomes by delivering innovative diagnostic tools that make a real difference in the healthcare sector.
Quidel Ortho Corp has a comprehensive product portfolio predominantly centered on infectious diseases, children's health, gastrointestinal diseases, autoimmune diseases, and bone health. It produces a broad array of diagnostic testing solutions, including immunoassays, molecular assays, and virology assays. These are provided under renowned brand names like Sofia®, QuickVue®, Lyra®, Triage®, InflammaDry®, and Solana®.
One of Quidel’s significant innovations is the various COVID-19 tests it has produced, including the first rapid antigen test to receive emergency use authorization from the FDA. This critical achievement illustrates the company's commitment to providing swift, reliable, and accessible COVID-19 testing efforts amidst the global pandemic.
Quidel Ortho Corp is consistently recognized for its innovation and excellence. The company possesses many FDA clearances and holds numerous patents related to its diagnostic healthcare advancements. Furthermore, its commitment to research and development is reflected in its ongoing collaborations with various universities, government centers, and commercial entities to further enhance its diagnostic product offerings.
As a public entity, Quidel Ortho Corp strongly values responsible conduct and transparency, adhering to stringent governance and compliance standards. It's dedicated to a corporate culture that emphasizes respect, integrity, and ethical behavior, supporting the well-being of patients, providers, employees, shareholders, and the communities in which it operates.
Overall, Quidel Ortho Corp plays an essential role in modern healthcare, providing diagnostic tools that enable healthcare professionals to provide better healthcare for their patients. Through its commitment to innovation, quality, and responsibility, the company continues to contribute positively to patient outcomes and the broader healthcare sector.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
QuidelOrtho's shares have fallen 60% in 2026 due to weak respiratory testing demand and policy worries. The company is addressing its balance sheet by exploring a US$1.5 billion sale of its point-of-care unit, which aligns with a cautious view focused on debt and cost pressure. While Q3 2026 revenue declined, net margin improved, and analysts believe cost cuts and cash generation efforts can reshape the company's future, assuming management delivers on sustained margin and free cash flow improvement.
QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline in Q3 2026 to $619 million, primarily due to destocking in China and a softer respiratory testing market. The company announced a cost transformation program aimed at over $80 million in annual savings for 2027 and is restructuring into core diagnostics and point-of-care diagnostics to improve focus and profitability. Despite a decline in gross margin and increased net leverage, free cash flow improved significantly to approximately breakeven.
QuidelOrtho reported Q3 2026 revenue of $619 million, a 12% year-over-year decrease, primarily due to new IVD pricing guidelines in China and a soft respiratory testing market. The company is implementing a new cost transformation and enterprise restructuring program, aiming for over $80 million in annual savings by 2027, and is reorganizing into Core Diagnostics and Point of Care Diagnostics to enhance profitability and focus. Full-year 2026 revenue guidance has been narrowed to $2.52-$2.54 billion, and management remains focused on improving free cash flow and reducing leverage.
Shares of QuidelOrtho (QDEL) rallied over 11% on Tuesday, rebounding from recent choppy trading that included a 7% decline last Friday. The stock closed at $14.21, up $1.45. Despite the rally, the company faces financial pressures including high leverage, negative free cash flow, and inventory buildup, with analysts remaining largely bearish due to these concerns and exposure to Chinese pricing reforms.